High frequency of acquired virulence factors in carbapenemase-producing Klebsiella pneumoniae isolates from a large German university hospital, 2013–2021
Antimicrobial Agents and Chemotherapy · 06.11.2024 · 68 (11)
DOI: 10.1128/aac.00602-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 06.11.2024. Verfasst von Janko Sattler und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Medical Microbiology, Immunology and Hygiene, University Hospital Cologne and Faculty of Medicine, University of Cologne, Cologne, Germ…. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, beta-Lactamases, Bacterial Proteins, Virulence Factors. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Carbapenemase-producing Klebsiella pneumoniae (CP-Kp) isolates are a public health concern as they can cause severe hospital-acquired infections that are difficult to treat. It has recently been shown that CP-Kp can take up virulence factors from hypervirulent K. pneumoniae lineages. In this study, 109 clinical CP-Kp isolates from the University Hospital Cologne were examined for the presence of acquired virulence factors using whole-genome sequencing and phenotypic tests, and results were linked to clinical data. The virulence factor iuc was present in 18/109 of the CP-Kp isolates. Other acquired virulence factors, such as ybt , cbt , iro , rmpA/rmpA2 , peg-344 , and hypervirulence-associated capsule types were detected in various combinations among these isolates. The iuc -positive isolates produced OXA-232 ( n = 7), OXA-48 ( n = 6), OXA-48+NDM ( n = 3), NDM, and KPC (each n = 1), and 7/18 isolates were resistant to ceftazidime-avibactam, colistin, and/or cefiderocol. Four isolates carried hybrid plasmids that harbored acquired virulence factors alongside the carbapenemase genes bla NDM-1/5 or bla OXA-48 . In 15/18 patients, iuc -positive CP-Kp were isolated from a clinically manifest infection site. Among these, four patients had osteomyelitis, and four patients died from pneumonia with OXA-232-producing ST231 isolates, three of them as part of an outbreak. In conclusion, acquired virulence factors are frequently detected in various combinations in carbapenemase-producing K. pneumoniae isolates in Germany, warranting continuous monitoring of infections caused by these strains.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Medical Microbiology, Immunology and Hygiene, University Hospital Cologne and Faculty of Medicine, University of Cologne, Cologne, Germany.
- Institute of Medical Microbiology and Virology, University of Oldenburg, Oldenburg, Germany.
- German Center for Infection Research (DZIF), Cologne, Germany.
- Department of Infection Control and Hospital Hygiene, University Hospital Cologne and Faculty of Medicine, University of Cologne, Cologne, Germany.
ORCID-Profile: Janko Sattler, Christoph M Ernst
Zitieren
APA
Sattler, J., Ernst, C. M., Zweigner, J., & Hamprecht, A. (2024). High frequency of acquired virulence factors in carbapenemase-producing Klebsiella pneumoniae isolates from a large German university hospital, 2013–2021. Antimicrobial Agents and Chemotherapy, 68(11). https://doi.org/10.1128/aac.00602-24
Vancouver
Sattler J, Ernst CM, Zweigner J, Hamprecht A. High frequency of acquired virulence factors in carbapenemase-producing Klebsiella pneumoniae isolates from a large German university hospital, 2013–2021. Antimicrobial Agents and Chemotherapy. 2024;68(11). doi:10.1128/aac.00602-24
BibTeX
@article{Sattler2024,
author = {Sattler, Janko and Ernst, Christoph M and Zweigner, Janine and Hamprecht, Axel},
title = {High frequency of acquired virulence factors in carbapenemase-producing Klebsiella pneumoniae isolates from a large German university hospital, 2013–2021},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
volume = {68},
number = {11},
doi = {10.1128/aac.00602-24}
}
EUVIMED